DXS International (AQSE:DXSP) EBITDA: £-0.13 Mil (TTM As of Apr. 2025)


What is DXS International EBITDA?

DXS International AQSE:DXSP EBITDA is £-0.13 Mil as of Apr. 2025. The stock has 2 warning signs investors should review.

DXS International's EBITDA for the six months ended in Apr. 2025 was £-0.13 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Apr. 2025 was £-0.13 Mil.

During the past 12 months, the average EBITDA Growth Rate of DXS International was -124.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 11 years, the highest 3-Year average EBITDA Growth Rate of DXS International was 42.80% per year. The lowest was -25.80% per year. And the median was 15.50% per year.

DXS International's EBITDA per Share for the twelve months ended in Apr. 2025 was £-0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Apr. 2025 was £-0.00.

During the past 12 months, the average EBITDA per Share Growth Rate of DXS International was -125.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 11 years, the highest 3-Year average EBITDA per Share Growth Rate of DXS International was 29.40% per year. The lowest was -32.50% per year. And the median was 15.90% per year.

DXS International  (AQSE:DXSP) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


DXS International EBITDA Related Terms


DXS International EBITDA Historical Data

* Premium members only.

The historical data trend for DXS International's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DXS International EBITDA Chart

DXS International Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.28 0.61 0.66 0.52 -0.13

DXS International Semi-Annual Data
Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.28 0.61 0.66 0.52 -0.13

AQSE:DXSP vs VEEV, BTSG, TEM: EBITDA Comparison

For the Health Information Services subindustry, DXS International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DXS International EV-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DXS International's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DXS International's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

DXS International's EBITDA for the fiscal year that ended in Apr. 2025 is calculated as

DXS International's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Apr. 2025, DXS International's EBITDA was £-0.13 Mil.

DXS International's EBITDA for the quarter that ended in Apr. 2025 is calculated as

DXS International's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Apr. 2025, DXS International's EBITDA was £-0.13 Mil.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBITDA for the trailing twelve months (TTM) ended in Apr. 2025 was £-0.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of £-0.13 Mil mean?
DXS International (AQSE:DXSP) has a EBITDA of £-0.13 Mil as of Apr. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on DXS International.
Is DXS International's EBITDA too high?
DXS International's current EBITDA is £-0.13 Mil.
How does DXS International's EBITDA compare to VEEV and BTSG?
DXS International's EBITDA of £-0.13 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Healthcare Providers & Services company?
A good EBITDA depends on the Healthcare Providers & Services industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on DXS International. DXS International's current EBITDA is £-0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
Based on GuruFocus' analysis, DXS International (AQSE:DXSP) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 37.5% below its estimated fair value. The current EBITDA is £-0.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For DXS International (AQSE:DXSP), the current EBITDA is £-0.13 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DXS International Business Description

Address 119 Saint Mary’s Road, Market Harborough, London, Leicestershire, GBR, LE16 7DT
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.